{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["cancer", "drug", "hepatocellular carcinoma", "molecular target", "phytochemicals", "signaling pathway"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34639131", "DateCompleted": {"Year": "2021", "Month": "10", "Day": "25"}, "DateRevised": {"Year": "2021", "Month": "10", "Day": "25"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "10", "Day": "06"}], "Language": ["eng"], "ELocationID": ["10774", "10.3390/ijms221910774"], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "22", "Issue": "19", "PubDate": {"Year": "2021", "Month": "Oct", "Day": "06"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "Anti-Hepatocellular Carcinoma Biomolecules: Molecular Targets Insights.", "Abstract": {"AbstractText": ["This report explores the available curative molecules directed against hepatocellular carcinoma (HCC). Limited efficiency as well as other drawbacks of existing molecules led to the search for promising potential alternatives. Understanding of the cell signaling mechanisms propelling carcinogenesis and driven by cell proliferation, invasion, and angiogenesis can offer valuable information for the investigation of efficient treatment strategies. The complexity of the mechanisms behind carcinogenesis inspires researchers to explore the ability of various biomolecules to target specific pathways. Natural components occurring mainly in food and medicinal plants, are considered an essential resource for discovering new and promising therapeutic molecules. Novel biomolecules normally have an advantage in terms of biosafety. They are also widely diverse and often possess potent antioxidant, anti-inflammatory, and anti-cancer properties. Based on quantitative structure-activity relationship studies, biomolecules can be used as templates for chemical modifications that improve efficiency, safety, and bioavailability. In this review, we focus on anti-HCC biomolecules that have their molecular targets partially or completely characterized as well as having anti-cancer molecular mechanisms that are fairly described."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biological Sciences, University of Jeddah, Jeddah 23445, Saudi Arabia."}], "LastName": "Juaid", "ForeName": "Nouf", "Initials": "N"}, {"Identifier": ["0000-0001-8888-1102"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biology Department, UAE University, Al Ain 15551, United Arab Emirates."}, {"Identifier": [], "Affiliation": "The College, The University of Chicago, Chicago, IL 60637, USA."}], "LastName": "Amin", "ForeName": "Amr", "Initials": "A"}, {"Identifier": ["0000-0002-1444-2112"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Weinberg Institute for Cognitive Science, University of Michigan, Ann Arbor, MI 48109, USA."}], "LastName": "Abdalla", "ForeName": "Ali", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Kinesiology, Michigan State University, East Lansing, MI 48824, USA."}], "LastName": "Reese", "ForeName": "Kevin", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biological Sciences, University of Jeddah, Jeddah 23445, Saudi Arabia."}], "LastName": "Alamri", "ForeName": "Zaenah", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Embryonic Stem Cell Research Unit, King Fahd Medical Research Center, King Abdul Aziz University, Jeddah 22252, Saudi Arabia."}], "LastName": "Moulay", "ForeName": "Mohamed", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biological Sciences, University of Jeddah, Jeddah 23445, Saudi Arabia."}], "LastName": "Abdu", "ForeName": "Suzan", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biological Sciences, University of Jeddah, Jeddah 23445, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Life Sciences Research Unit, Center for Sciences and Medical Research, University of Jeddah, Osfan Road, Jeddah 23445, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Functional Genomics and Plant Physiology Research Unit, Higher Institute of Biotechnology Sfax, University of Sfax, BP261 Road Soukra Km4, Sfax 3038, Tunisia."}], "LastName": "Miled", "ForeName": "Nabil", "Initials": "N"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Neoplasm Proteins"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": ["drug therapy", "metabolism", "pathology"], "DescriptorName": "Carcinoma, Hepatocellular"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy", "metabolism", "pathology"], "DescriptorName": "Liver Neoplasms"}, {"QualifierName": [], "DescriptorName": "Molecular Targeted Therapy"}, {"QualifierName": ["antagonists & inhibitors"], "DescriptorName": "Neoplasm Proteins"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116:855\u2013867. doi: 10.1016/S0092-8674(04)00215-6.", "ArticleIdList": ["10.1016/S0092-8674(04)00215-6", "15035987"]}, {"Citation": "Singal A.G., Lampertico P., Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J. Hepatol. 2020;72:250\u2013261. doi: 10.1016/j.jhep.2019.08.025.", "ArticleIdList": ["10.1016/j.jhep.2019.08.025", "PMC6986771", "31954490"]}, {"Citation": "Petrick J.L., Braunlin M., Laversanne M., Valery P.C., Bray F., McGlynn K.A. International trends in liver cancer incidence, overall and by histologic subtype, 1978\u20132007. Int. J. Cancer. 2016;139:1534\u20131545. doi: 10.1002/ijc.30211.", "ArticleIdList": ["10.1002/ijc.30211", "PMC5310166", "27244487"]}, {"Citation": "Chow A.K.-M., Yau S.W.-L., Ng L. Novel molecular targets in hepatocellular carcinoma. World J. Clin. Oncol. 2020;11:589\u2013605. doi: 10.5306/wjco.v11.i8.589.", "ArticleIdList": ["10.5306/wjco.v11.i8.589", "PMC7443834", "32879846"]}, {"Citation": "Clark R., Lee S.-H. Anticancer properties of capsaicin against human cancer. Anticancer Res. 2016;36:837\u2013843.", "ArticleIdList": ["26976969"]}, {"Citation": "Okuda H. Hepatocellular carcinoma development in cirrhosis. Best Pract. Res. Clin. Gastroenterol. 2007;21:161\u2013173. doi: 10.1016/j.bpg.2006.07.002.", "ArticleIdList": ["10.1016/j.bpg.2006.07.002", "17223503"]}, {"Citation": "Salem R., Lewandowski R.J. Chemoembolization and radioembolization for hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 2013;11:604\u2013611. doi: 10.1016/j.cgh.2012.12.039.", "ArticleIdList": ["10.1016/j.cgh.2012.12.039", "PMC3800021", "23357493"]}, {"Citation": "Wilkes G.M. Targeted therapy: Attacking cancer with molecular and immunological targeted agents. Asia-Pacific J. Oncol. Nurs. 2018;5:137\u2013155. doi: 10.4103/apjon.apjon_79_17.", "ArticleIdList": ["10.4103/apjon.apjon_79_17", "PMC5863423", "29607374"]}, {"Citation": "Parveen A., Subedi L., Kim H.W., Khan Z., Zahra Z., Farooqi M.Q., Kim S.Y. Phytochemicals targeting VEGF and VEGF-related multifactors as anticancer therapy. J. Clin. Med. 2019;8:350. doi: 10.3390/jcm8030350.", "ArticleIdList": ["10.3390/jcm8030350", "PMC6462934", "30871059"]}, {"Citation": "Gauthier A., Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatol. Res. 2013;43:147\u2013154. doi: 10.1111/j.1872-034X.2012.01113.x.", "ArticleIdList": ["10.1111/j.1872-034X.2012.01113.x", "PMC3574194", "23145926"]}, {"Citation": "Peer C.J., Sissung T.M., Kim A., Jain L., Woo S., Gardner E.R., Kirkland C.T., Troutman S.M., English B.C., Richardson E.D., et al. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: Implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin. Cancer Res. 2012;18:2099\u20132107. doi: 10.1158/1078-0432.CCR-11-2484.", "ArticleIdList": ["10.1158/1078-0432.CCR-11-2484", "PMC6432766", "22307138"]}, {"Citation": "Wilhelm S.M., Adnane L., Newell P., Villanueva A., Llovet J.M., Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 2008;7:3129\u20133140. doi: 10.1158/1535-7163.MCT-08-0013.", "ArticleIdList": ["10.1158/1535-7163.MCT-08-0013", "18852116"]}, {"Citation": "Lee S., Loecher M., Iyer R. Immunomodulation in hepatocellular cancer. J. Gastrointest. Oncol. 2018;9:208\u2013219. doi: 10.21037/jgo.2017.06.08.", "ArticleIdList": ["10.21037/jgo.2017.06.08", "PMC5848038", "29564186"]}, {"Citation": "Raoul J.-L., Bruix J., Greten T.F., Sherman M., Mazzaferro V.M., Hilgard P., Scherubl H., Scheulen M.E., Germanidis G., Dominguez S., et al. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J. Hepatol. 2012;56:1080\u20131088. doi: 10.1016/j.jhep.2011.12.009.", "ArticleIdList": ["10.1016/j.jhep.2011.12.009", "22245896"]}, {"Citation": "Cuestas M.L., Oubi\u00f1a J.R., Mathet V.L. Hepatocellular carcinoma and multidrug resistance: Past, present and new challenges for therapy improvement. World J. Pharmacol. 2015;4:96\u2013116. doi: 10.5497/wjp.v4.i1.96.", "ArticleIdList": ["10.5497/wjp.v4.i1.96"]}, {"Citation": "Keating G.M. Sorafenib: A review in hepatocellular carcinoma. Proteins. 2017;4:5. doi: 10.1007/s11523-017-0484-7.", "ArticleIdList": ["10.1007/s11523-017-0484-7", "28299600"]}, {"Citation": "Chen K.-F., Chen H.-L., Tai W.-T., Feng W.-C., Hsu C.-H., Chen P.-J., Cheng A.-L. Activation of phosphatidylin-ositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J. Pharmacol. Exp. Ther. 2011;337:155\u2013161. doi: 10.1124/jpet.110.175786.", "ArticleIdList": ["10.1124/jpet.110.175786", "21205925"]}, {"Citation": "Toh T.B., Lim J.J., Hooi L., Rashid M.B.M.A., Chow E.K.-H. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/\u03b2-catenin-driven hepatocellular carcinoma. J. Hepatol. 2020;72:104\u2013118. doi: 10.1016/j.jhep.2019.08.035.", "ArticleIdList": ["10.1016/j.jhep.2019.08.035", "31541681"]}, {"Citation": "Koeberle D., Dufour J.-F., Demeter G., Li Q., Ribi K., Samaras P., Saletti P., Roth A., Horber D., Buehlmann M., et al. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): A randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29) Ann. Oncol. 2016;27:856\u2013861. doi: 10.1093/annonc/mdw054.", "ArticleIdList": ["10.1093/annonc/mdw054", "26884590"]}, {"Citation": "Breuleux M., Klopfenstein M., Stephan C., Doughty C.A., Barys L., Maira S.-M., Kwiatkowski D., Lane H.A. In-creased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol. Cancer Ther. 2009;8:742\u2013753. doi: 10.1158/1535-7163.MCT-08-0668.", "ArticleIdList": ["10.1158/1535-7163.MCT-08-0668", "PMC3440776", "19372546"]}, {"Citation": "Jiang H., Wu D., Xu D., Yu H., Zhao Z., Ma D., Jin J. Eupafolin exhibits potent anti-angiogenic and antitumor ac-tivity in hepatocellular carcinoma. Int. J. Biol. Sci. 2017;13:701. doi: 10.7150/ijbs.17534.", "ArticleIdList": ["10.7150/ijbs.17534", "PMC5485626", "28655996"]}, {"Citation": "Lowinger T., Riedl B., Dumas J., Smith R. Design and discovery of small molecules targeting Raf-1 kinase. Curr. Pharm. Des. 2002;8:2269\u20132278. doi: 10.2174/1381612023393125.", "ArticleIdList": ["10.2174/1381612023393125", "12369855"]}, {"Citation": "Nagar B., Bornmann W.G., Pellicena P., Schindler T., Veach D.R., Miller W.T., Clarkson B., Kuriyan J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) Cancer Res. 2002;62:4236\u20134243.", "ArticleIdList": ["12154025"]}, {"Citation": "Pargellis C., Tong L., Churchill L., Cirillo P.F., Gilmore T., Graham A.G., Grob P.M., Hickey E.R., Moss N., Pav S., et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 2002;9:268\u2013272. doi: 10.1038/nsb770.", "ArticleIdList": ["10.1038/nsb770", "11896401"]}, {"Citation": "Wu C., Wang M., Tang Q., Luo R., Chen L., Zheng P., Zhu W. Design, synthesis, activity and docking study of sorafenib analogs bearing sulfonylurea unit. Molecules. 2015;20:19361\u201319371. doi: 10.3390/molecules201019361.", "ArticleIdList": ["10.3390/molecules201019361", "PMC6332012", "26512636"]}, {"Citation": "Yao J., Chen J., He Z., Sun W., Xu W. Design, synthesis and biological activities of thiourea containing sorafenib analogs as antitumor agents. Bioorg. Med. Chem. 2012;20:2923\u20132929. doi: 10.1016/j.bmc.2012.03.018.", "ArticleIdList": ["10.1016/j.bmc.2012.03.018", "22483592"]}, {"Citation": "Wang M., Xu S., Wu C., Liu X., Tao H., Huang Y., Liu Y., Zheng P., Zhu W. Design, synthesis and activity of novel sorafenib analogues bearing chalcone unit. Bioorg. Med. Chem. Lett. 2016;26:5450\u20135454. doi: 10.1016/j.bmcl.2016.10.029.", "ArticleIdList": ["10.1016/j.bmcl.2016.10.029", "27777009"]}, {"Citation": "Finn R.S., Kang Y.-K., Mulcahy M., Polite B.N., Lim H.Y., Walters I., Baudelet C., Manekas D., Park J.-W. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 2012;18:2090\u20132098. doi: 10.1158/1078-0432.CCR-11-1991.", "ArticleIdList": ["10.1158/1078-0432.CCR-11-1991", "22238246"]}, {"Citation": "Huynh H., Ngo V.C., Fargnoli J., Ayers M., Soo K.C., Koong H.N., Thng C.H., Ong H.S., Chung A., Chow P., et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin. Cancer Res. 2008;14:6146\u20136153. doi: 10.1158/1078-0432.CCR-08-0509.", "ArticleIdList": ["10.1158/1078-0432.CCR-08-0509", "18829493"]}, {"Citation": "Alberts S.R., Fitch T.R., Kim G.P., Morlan B.W., Dakhil S.R., Gross H.M., Nair S. Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: A phase II north central cancer treatment group (NCCTG) Clinical Trial. Am. J. Clin. Oncol. 2012;35:329. doi: 10.1097/COC.0b013e3182118cdf.", "ArticleIdList": ["10.1097/COC.0b013e3182118cdf", "PMC3126867", "21422991"]}, {"Citation": "Huynh H., Chow P., Tai W.M., Choo S.P., Chung A.Y.F., Ong H.S., Soo K.C., Ong R., Linnartz R., Shi M.M. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. J. Hepatol. 2012;56:595\u2013601. doi: 10.1016/j.jhep.2011.09.017.", "ArticleIdList": ["10.1016/j.jhep.2011.09.017", "22027573"]}, {"Citation": "Cheng A.-L., Thongprasert S., Lim H.Y., Sukeepaisarnjaroen W., Yang T.-S., Wu C.-C., Chao Y., Chan S., Kudo M., Ikeda M., et al. Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. Hepatology. 2016;64:774\u2013784. doi: 10.1002/hep.28600.", "ArticleIdList": ["10.1002/hep.28600", "27082062"]}, {"Citation": "Philip P.A., Mahoney M.R., Allmer C., Thomas J., Pitot H.C., Kim G., Donehower R.C., Fitch T., Picus J., Erlichman C. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J. Clin. Oncol. 2005;23:6657\u20136663. doi: 10.1200/JCO.2005.14.696.", "ArticleIdList": ["10.1200/JCO.2005.14.696", "16170173"]}, {"Citation": "Thomas M.B., Chadha R., Glover K., Wang X., Morris J., Brown T., Rashid A., Dancey J., Abbruzzese J.L. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer. 2007;110:1059\u20131067. doi: 10.1002/cncr.22886.", "ArticleIdList": ["10.1002/cncr.22886", "17623837"]}, {"Citation": "Zhu B.-D., Yuan S.-J., Zhao Q.-C., Li X., Li Y., Lu Q.-Y. Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma. World J. Gastroenterol. 2005;11:1382\u20131386. doi: 10.3748/wjg.v11.i9.1382.", "ArticleIdList": ["10.3748/wjg.v11.i9.1382", "PMC4250690", "15761981"]}, {"Citation": "O\u2019Neil B.H., Goff L.W., Kauh J.S.W., Strosberg J.R., Bekaii-Saab T.S., Lee R.-m., Kazi A., Moore D.T., Learoyd M., Lush R.M., et al. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepa-tocellular carcinoma. J. Clin. Oncol. 2011;29:2350. doi: 10.1200/JCO.2010.33.9432.", "ArticleIdList": ["10.1200/JCO.2010.33.9432", "PMC3107750", "21519015"]}, {"Citation": "Yi T., Cho S.-G., Yi Z., Pang X., Rodriguez M., Wang Y., Sethi G., Aggarwal B.B., Liu M. Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol. Cancer Ther. 2008;7:1789\u20131796. doi: 10.1158/1535-7163.MCT-08-0124.", "ArticleIdList": ["10.1158/1535-7163.MCT-08-0124", "PMC2587125", "18644991"]}, {"Citation": "Cainap C., Qin S., Huang W.-T., Chung I.J., Pan H., Cheng Y., Kudo M., Kang Y.-K., Chen P.-J., Toh H.-C. Li-nifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial. J. Clin. Oncol. 2015;33:172. doi: 10.1200/JCO.2013.54.3298.", "ArticleIdList": ["10.1200/JCO.2013.54.3298", "PMC4279237", "25488963"]}, {"Citation": "Toh H.C., Chen P.-J., Carr B., Knox J.J., Gill S., Ansell P., McKeegan E.M., Dowell B., Pedersen M., Qin Q., et al. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer. 2013;119:380\u2013387. doi: 10.1002/cncr.27758.", "ArticleIdList": ["10.1002/cncr.27758", "22833179"]}, {"Citation": "Jasinghe V.J., Xie Z., Zhou J., Khng J., Poon L.-F., Senthilnathan P., Glaser K.B., Albert D.H., Davidsen S.K., Chen C.-S. ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepa-tocellular carcinoma xenograft. J. Hepatol. 2008;49:985\u2013997. doi: 10.1016/j.jhep.2008.08.010.", "ArticleIdList": ["10.1016/j.jhep.2008.08.010", "18930332"]}, {"Citation": "Zhu A.X., Sahani D.V., Duda D.G., di Tomaso E., Ancukiewicz M., Catalano O.A., Sindhwani V., Blaszkowsky L.S., Yoon S.S., Lahdenranta J., et al. Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study. J. Clin. Oncol. 2009;27:3027\u20133035. doi: 10.1200/JCO.2008.20.9908.", "ArticleIdList": ["10.1200/JCO.2008.20.9908", "PMC2702235", "19470923"]}, {"Citation": "Kanai F., Yoshida H., Tateishi R., Sato S., Kawabe T., Obi S., Kondo Y., Taniguchi M., Tagawa K., Ikeda M., et al. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother. Pharmacol. 2010;67:315\u2013324. doi: 10.1007/s00280-010-1320-2.", "ArticleIdList": ["10.1007/s00280-010-1320-2", "20390419"]}, {"Citation": "Kudo M., Cheng A.-L., Park J.-W., Park J.H., Liang P.-C., Hidaka H., Izumi N., Heo J., Lee Y.J., Sheen I.-S., et al. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): A randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet Gastroenterol. Hepatol. 2018;3:37\u201346. doi: 10.1016/S2468-1253(17)30290-X.", "ArticleIdList": ["10.1016/S2468-1253(17)30290-X", "28988687"]}, {"Citation": "Siegel A.B., Cohen E.I., Ocean A., Lehrer D., Goldenberg A., Knox J.J., Chen H., Clark-Garvey S., Weinberg A., Mandeli J., et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J. Clin. Oncol. 2008;26:2992\u20132998. doi: 10.1200/JCO.2007.15.9947.", "ArticleIdList": ["10.1200/JCO.2007.15.9947", "PMC3635806", "18565886"]}, {"Citation": "Kubota M., Shimizu M., Baba A., Ohno T., Kochi T., Shirakami Y., Moriwaki H. Combination of bevacizumab and acyclic retinoid inhibits the growth of hepatocellular carcinoma xenografts. J. Nutr. Sci. Vitaminol. 2014;60:357\u2013362. doi: 10.3177/jnsv.60.357.", "ArticleIdList": ["10.3177/jnsv.60.357", "25744425"]}, {"Citation": "Zhu A.X., Stuart K., Blaszkowsky L.S., Ma A.M., Reitberg D.P., Clark J.W., Enzinger P.C., Bhargava P., Meyerhardt J.A., Horgan K., et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer Interdiscip. Int. J. Am. Cancer Soc. 2007;110:581\u2013589. doi: 10.1002/cncr.22829.", "ArticleIdList": ["10.1002/cncr.22829", "17583545"]}, {"Citation": "Llovet J.M., Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J. Hepatol. 2008;48:S20\u2013S37. doi: 10.1016/j.jhep.2008.01.022.", "ArticleIdList": ["10.1016/j.jhep.2008.01.022", "18304676"]}, {"Citation": "Peters B.M.L., Miksad R.A. Cabozantinib in the treatment of hepatocellular carcinoma. Future Oncol. 2017;13:1915\u20131929. doi: 10.2217/fon-2017-0169.", "ArticleIdList": ["10.2217/fon-2017-0169", "28703624"]}, {"Citation": "Cao H., Phan H., Yang L.-X. Improved chemotherapy for hepatocellular carcinoma. Anticancer Res. 2012;32:1379\u20131386.", "ArticleIdList": ["22493374"]}, {"Citation": "You H., Ding W., Dang H., Jiang Y., Rountree C.B. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology. 2011;54:879\u2013889. doi: 10.1002/hep.24450.", "ArticleIdList": ["10.1002/hep.24450", "PMC3181384", "21618573"]}, {"Citation": "Zhang W.-G., Yin X.-C., Liu X.-F., Meng K.-W., Tang K., Huang F.-L., Xu G., Gao J. Puerarin induces hepatocellular car-cinoma cell apoptosis modulated by MAPK signaling pathways in a dose-dependent manner. Anticancer. Res. 2017;37:4425\u20134431.", "ArticleIdList": ["28739736"]}, {"Citation": "Stephens L., Eguinoa A., Erdjument-Bromage H., Lui M., Cooke F., Coadwell J., Smrcka A., Thelen M., Cadwallader K., Tempst P., et al. The G\u03b2\u03b3 sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. Cell. 1997;89:105\u2013114. doi: 10.1016/S0092-8674(00)80187-7.", "ArticleIdList": ["10.1016/S0092-8674(00)80187-7", "9094719"]}, {"Citation": "Franke T.F., Yang S.-I., Chan T., Datta K., Kazlauskas A., Morrison D.K., Kaplan D.R., Tsichlis P.N. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell. 1995;81:727\u2013736. doi: 10.1016/0092-8674(95)90534-0.", "ArticleIdList": ["10.1016/0092-8674(95)90534-0", "7774014"]}, {"Citation": "Klippel A., Kavanaugh W.M., Pot D., Williams L.T. A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain. Mol. Cell. Biol. 1997;17:338\u2013344. doi: 10.1128/MCB.17.1.338.", "ArticleIdList": ["10.1128/MCB.17.1.338", "PMC231758", "8972214"]}, {"Citation": "Matter M., Decaens T., Andersen J.B., Thorgeirsson S.S. Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends. J. Hepatol. 2014;60:855\u2013865. doi: 10.1016/j.jhep.2013.11.031.", "ArticleIdList": ["10.1016/j.jhep.2013.11.031", "PMC3960348", "24308993"]}, {"Citation": "Kunter I., Erdal E., Nart D., Yilmaz F., Karademir S., Sagol O., Atabey N. Active form of AKT controls cell proliferation and response to apoptosis in hepatocellular carcinoma. Oncol. Rep. 2014;31:573\u2013580. doi: 10.3892/or.2013.2932.", "ArticleIdList": ["10.3892/or.2013.2932", "PMC3896502", "24337632"]}, {"Citation": "Zhou Y., Zhang M., Zhang Z., Jia Y., Zhang C., Peng L. Hydrazinocurcumin and 5-fluorouracil enhance apoptosis and restrain tumorigenicity of HepG2 cells via disrupting the PTEN-mediated PI3K/Akt signaling pathway. Biomed. Pharmacother. 2020;129:109851. doi: 10.1016/j.biopha.2020.109851.", "ArticleIdList": ["10.1016/j.biopha.2020.109851", "32559627"]}, {"Citation": "Viollet B., Guigas B., Leclerc J., H\u00e9brard S., Lantier L., Mounier R., Andreelli F., Foretz M. AMP-activated protein kinase in the regulation of hepatic energy metabolism: From physiology to therapeutic perspectives. Acta Physiol. 2009;196:81\u201398. doi: 10.1111/j.1748-1716.2009.01970.x.", "ArticleIdList": ["10.1111/j.1748-1716.2009.01970.x", "PMC2956117", "19245656"]}, {"Citation": "Fasolo A., Sessa C. Targeting mTOR pathways in human malignancies. Curr. Pharm. Des. 2012;18:2766\u20132777. doi: 10.2174/138161212800626210.", "ArticleIdList": ["10.2174/138161212800626210", "22475451"]}, {"Citation": "Wang Z., Fan J., Zhou J., Wu Z.-Q., Qiu S.-J., Yu Y., Huang X.-W., Tang Z.-Y. Inhibition of growth and metastasis of hepatocellular carcinoma by rapamycin: Experiment with mice. Zhonghua Yi Xue Za Zhi. 2006;86:1666\u20131670.", "ArticleIdList": ["16854316"]}, {"Citation": "Piguet A.-C., Saar B., Hlushchuk R., St-Pierre M.V., McSheehy P.M.J., Radojevic V., Afthinos M., Terracciano L., Djonov V., Dufour J.-F. everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Mol. Cancer Ther. 2011;10:1007\u20131017. doi: 10.1158/1535-7163.MCT-10-0666.", "ArticleIdList": ["10.1158/1535-7163.MCT-10-0666", "21487053"]}, {"Citation": "Huynh H., Chow K.P., Soo K.C., Toh H.C., Choo S.P., Foo K.F., Poon D., Ngo V.C., Tran E. RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J. Cell. Mol. Med. 2009;13:1371\u20131380. doi: 10.1111/j.1582-4934.2008.00364.x.", "ArticleIdList": ["10.1111/j.1582-4934.2008.00364.x", "PMC4496150", "18466352"]}, {"Citation": "Zhou P., Yang X.-L., Wang X.-G., Hu B., Zhang L., Zhang W., Si H.-R., Zhu Y., Li B., Huang C.-L., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270\u2013273. doi: 10.1038/s41586-020-2012-7.", "ArticleIdList": ["10.1038/s41586-020-2012-7", "PMC7095418", "32015507"]}, {"Citation": "Thomas S.J., Snowden J.A., Zeidler M., Danson S. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br. J. Cancer. 2015;113:365\u2013371. doi: 10.1038/bjc.2015.233.", "ArticleIdList": ["10.1038/bjc.2015.233", "PMC4522639", "26151455"]}, {"Citation": "Svinka J., Mikulits W., Eferl R. STAT3 in hepatocellular carcinoma: New perspectives. Hepatic Oncol. 2014;1:107\u2013120. doi: 10.2217/hep.13.7.", "ArticleIdList": ["10.2217/hep.13.7", "PMC6114013", "30190945"]}, {"Citation": "Rosmorduc O., Desbois-Mouthon C. Targeting STAT3 in hepatocellular carcinoma: Sorafenib again. J. Hepatol. 2011;55:957\u2013959. doi: 10.1016/j.jhep.2011.06.005.", "ArticleIdList": ["10.1016/j.jhep.2011.06.005", "21718664"]}, {"Citation": "Wang X., Liao X., Yu T., Gong Y., Zhang L., Huang J., Yang C., Han C., Yu L., Zhu G., et al. Analysis of clinical significance and prospective molecular mechanism of main elements of the JAK/STAT pathway in hepatocellular carcinoma. Int. J. Oncol. 2019;55:805\u2013822. doi: 10.3892/ijo.2019.4862.", "ArticleIdList": ["10.3892/ijo.2019.4862", "PMC6741847", "31485610"]}, {"Citation": "Calvisi D.F., Ladu S., Gorden A., Farina M., Conner E.A., Lee J., Factor V.M., Thorgeirsson S.S. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology. 2006;130:1117\u20131128. doi: 10.1053/j.gastro.2006.01.006.", "ArticleIdList": ["10.1053/j.gastro.2006.01.006", "16618406"]}, {"Citation": "Tang J.J.H., Thng D.K.H., Lim J.J., Toh T.B. JAK/STAT signaling in hepatocellular carcinoma. Hepatic Oncol. 2020;7:HEP18. doi: 10.2217/hep-2020-0001.", "ArticleIdList": ["10.2217/hep-2020-0001", "PMC7137178", "32273976"]}, {"Citation": "Wonganan O., He Y.-J., Shen X.-F., Wongkrajang K., Suksamrarn A., Zhang G.-L., Wang F. 6-Hydroxy-3-O-methyl-kaempferol 6-O-glucopyranoside potentiates the anti-proliferative effect of interferon \u03b1/\u03b2 by promoting activation of the JAK/STAT signaling by inhibiting SOCS3 in hepatocellular carcinoma cells. Toxicol. Appl. Pharmacol. 2017;336:31\u201339. doi: 10.1016/j.taap.2017.10.004.", "ArticleIdList": ["10.1016/j.taap.2017.10.004", "29031523"]}, {"Citation": "He G., Karin M. NF-\u03baB and STAT3\u2013key players in liver inflammation and cancer. Cell. Res. 2011;21:159\u2013168. doi: 10.1038/cr.2010.183.", "ArticleIdList": ["10.1038/cr.2010.183", "PMC3193410", "21187858"]}, {"Citation": "Yang L., Lin S., Xu L., Lin J., Zhao C., Huang X. Novel activators and small-molecule inhibitors of STAT3 in cancer. Cytokine Growth Factor Rev. 2019;49:10\u201322. doi: 10.1016/j.cytogfr.2019.10.005.", "ArticleIdList": ["10.1016/j.cytogfr.2019.10.005", "31677966"]}, {"Citation": "Xu G., Zhu L., Wang Y., Shi Y., Gong A., Wu C. Stattic Enhances Radiosensitivity and Reduces Radio-Induced Migration and Invasion in HCC Cell Lines through an Apoptosis Pathway. BioMed Res. Int. 2017;2017:1832494. doi: 10.1155/2017/1832494.", "ArticleIdList": ["10.1155/2017/1832494", "PMC5684518", "29226125"]}, {"Citation": "Li S., Yao J., Xie M., Liu Y., Zheng M. Exosomal miRNAs in hepatocellular carcinoma development and clinical responses. J. Hematol. Oncol. 2018;11:1\u20139. doi: 10.1186/s13045-018-0579-3.", "ArticleIdList": ["10.1186/s13045-018-0579-3", "PMC5896112", "29642941"]}, {"Citation": "Xie M., A Steitz J. Versatile microRNA biogenesis in animals and their viruses. RNA Biol. 2014;11:673\u2013681. doi: 10.4161/rna.28985.", "ArticleIdList": ["10.4161/rna.28985", "PMC4156499", "24823351"]}, {"Citation": "Wong C.-M., Tsang F.H., Ng I.O. Non-coding RNAs in hepatocellular carcinoma: Molecular functions and pathological implications. Nat. Rev. Gastroenterol. Hepatol. 2018;15:137\u2013151. doi: 10.1038/nrgastro.2017.169.", "ArticleIdList": ["10.1038/nrgastro.2017.169", "29317776"]}, {"Citation": "Braconi C., Valeri N., Kogure T., Gasparini P., Huang N., Nuovo G.J., Terracciano L., Croce C.M., Patel T. Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA. 2011;108:786\u2013791. doi: 10.1073/pnas.1011098108.", "ArticleIdList": ["10.1073/pnas.1011098108", "PMC3021052", "21187392"]}, {"Citation": "Kogure T., Lin W.-L., Yan I.K., Braconi C., Patel T. Intercellular nanovesicle-mediated microRNA transfer: A mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology. 2011;54:1237\u20131248. doi: 10.1002/hep.24504.", "ArticleIdList": ["10.1002/hep.24504", "PMC3310362", "21721029"]}, {"Citation": "Chen H., Huang Y., Huang J., Lin L., Wei G. Gigantol attenuates the proliferation of human liver cancer HepG2 cells through the PI3K/Akt/NF-\u03baB signaling pathway. Oncol. Rep. 2017;37:865\u2013870. doi: 10.3892/or.2016.5299.", "ArticleIdList": ["10.3892/or.2016.5299", "27959444"]}, {"Citation": "Huang J.-Y., Zhang K., Chen D.-Q., Chen J., Feng B., Song H., Chen Y., Zhu Z., Lu L., De W., et al. MicroRNA-451: Epitheli-al-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma. Oncotarget. 2015;6:18613. doi: 10.18632/oncotarget.4317.", "ArticleIdList": ["10.18632/oncotarget.4317", "PMC4621914", "26164082"]}, {"Citation": "Hsu S.-H., Wang B., Kota J., Yu J., Costinean S., Kutay H., Yu L., Bai S., La Perle K., Chivukula R.R., et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J. Clin. Investig. 2012;122:2871\u20132883. doi: 10.1172/JCI63539.", "ArticleIdList": ["10.1172/JCI63539", "PMC3408748", "22820288"]}, {"Citation": "Zeisel M.B., Felmlee D.J., Baumert T.F. Hepatitis C virus entry. Hepat. C Virus Mol. Virol. Antivir. Ther. 2013;369:87\u2013112.", "ArticleIdList": ["23463198"]}, {"Citation": "Chen C.-L., Wu J.-C., Chen G.-Y., Yuan P.-H., Tseng Y.-W., Li K.-C., Hwang S.-M., Hu Y.-C. Baculovirus-mediated miRNA regulation to suppress hepatocellular carcinoma tumorigenicity and metastasis. Mol. Ther. 2015;23:79\u201388. doi: 10.1038/mt.2014.126.", "ArticleIdList": ["10.1038/mt.2014.126", "PMC4426788", "25023326"]}, {"Citation": "Wang F., Li L., Piontek K., Sakaguchi M., Selaru F.M. Exosome miR-335 as a novel therapeutic strategy in hepatocellular carcinoma. Hepatology. 2018;67:940\u2013954. doi: 10.1002/hep.29586.", "ArticleIdList": ["10.1002/hep.29586", "PMC5826829", "29023935"]}, {"Citation": "Tang J., Li Y., Liu K., Zhu Q., Yang W.-H., Xiong L.-K., Guo D.-L. Exosomal miR-9-3p suppresses HBGF-5 expression and is a functional biomarker in hepatocellular carcinoma. Minerva Med. 2017;109:15\u201323. doi: 10.23736/S0026-4806.17.05167-9.", "ArticleIdList": ["10.23736/S0026-4806.17.05167-9", "28750499"]}, {"Citation": "Xiong L., Zhen S., Yu Q., Gong Z. HCV-E2 inhibits hepatocellular carcinoma metastasis by stimulating mast cells to secrete exosomal shuttle microRNAs. Oncol. Lett. 2017;14:2141\u20132146. doi: 10.3892/ol.2017.6433.", "ArticleIdList": ["10.3892/ol.2017.6433", "PMC5530191", "28781655"]}, {"Citation": "Jin F., Wang Y., Li M., Zhu Y., Liang H., Wang C., Wang F., Zhang C.-Y., Zen K., Li L. MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy. Cell Death Dis. 2018;8:e2540. doi: 10.1038/cddis.2016.461.", "ArticleIdList": ["10.1038/cddis.2016.461", "PMC5386370", "28079894"]}, {"Citation": "Afrin R., Arumugam S., Rahman A., Wahed M.I.I., Karuppagounder V., Harima M., Suzuki H., Miyashita S., Suzuki K., Yoneyama H., et al. Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by mod-ulating HMGB1-NF-\u03baB translocation. Int. Immunopharmacol. 2017;44:174\u2013182. doi: 10.1016/j.intimp.2017.01.016.", "ArticleIdList": ["10.1016/j.intimp.2017.01.016", "28110063"]}, {"Citation": "Yan Y., Liu N., Hou N., Dong L., Li J. Chlorogenic acid inhibits hepatocellular carcinoma in vitro and in vivo. J. Nutr. Biochem. 2017;46:68\u201373. doi: 10.1016/j.jnutbio.2017.04.007.", "ArticleIdList": ["10.1016/j.jnutbio.2017.04.007", "28458139"]}, {"Citation": "Jagan S., Ramakrishnan G., Anandakumar P., Kamaraj S., Devaki T. Antiproliferative potential of gallic acid against di-ethylnitrosamine-induced rat hepatocellular carcinoma. Mol. Cell. Biochem. 2008;319:51\u201359. doi: 10.1007/s11010-008-9876-4.", "ArticleIdList": ["10.1007/s11010-008-9876-4", "18629614"]}, {"Citation": "Chen Y., Zhou B., Xu L., Fan H., Xie J., Wang D. MicroRNA-146a promotes gastric cancer cell apoptosis by targeting transforming growth factor \u03b2-activated kinase 1. Mol. Med. Rep. 2017;16:755\u2013763. doi: 10.3892/mmr.2017.6640.", "ArticleIdList": ["10.3892/mmr.2017.6640", "PMC5482191", "28560435"]}, {"Citation": "Yu H., Pan C., Zhao S., Wang Z., Zhang H., Wu W. Resveratrol inhibits tumor necrosis factor-\u03b1-mediated matrix metal-loproteinase-9 expression and invasion of human hepatocellular carcinoma cells. Biomed. Pharmacother. 2008;62:366\u2013372. doi: 10.1016/j.biopha.2007.09.006.", "ArticleIdList": ["10.1016/j.biopha.2007.09.006", "17988825"]}, {"Citation": "Pei T., Meng Q., Han J., Sun H., Li L., Song R., Sun B., Pan S., Liang D., Liu L. (\u2212)-Oleocanthal inhibits growth and metastasis by blocking activation of STAT3 in human hepatocellular carcinoma. Oncotarget. 2016;7:43475\u201343491. doi: 10.18632/oncotarget.9782.", "ArticleIdList": ["10.18632/oncotarget.9782", "PMC5190038", "27259268"]}, {"Citation": "Liu L., Qin S., Zheng Y., Han L., Zhang M., Luo N., Liu Z., Gu N., Gu X., Yin X. Molecular targeting of VEGF/VEGFR signaling by the anti-VEGF monoclonal antibody BD0801 inhibits the growth and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo. Cancer Biol. Ther. 2017;18:166\u2013176. doi: 10.1080/15384047.2017.1282019.", "ArticleIdList": ["10.1080/15384047.2017.1282019", "PMC5389424", "28368741"]}, {"Citation": "Agullo G., Gamet-Payrastre L., Manenti S., Viala C., R\u00e9m\u00e9sy C., Chap H., Payrastre B. Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: A comparison with tyrosine kinase and protein kinase C inhibition. Biochem. Pharmacol. 1997;53:1649\u20131657. doi: 10.1016/S0006-2952(97)82453-7.", "ArticleIdList": ["10.1016/S0006-2952(97)82453-7", "9264317"]}, {"Citation": "Peet G.W., Li J. I\u03baB kinases \u03b1 and \u03b2 show a random sequential kinetic mechanism and are inhibited by staurosporine and quercetin. J. Biol. Chem. 1999;274:32655\u201332661. doi: 10.1074/jbc.274.46.32655.", "ArticleIdList": ["10.1074/jbc.274.46.32655", "10551820"]}, {"Citation": "Maurya A.K., Vinayak M. Anticarcinogenic action of quercetin by downregulation of phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC) via induction of p53 in hepatocellular carcinoma (HepG2) cell line. Mol. Biol. Rep. 2015;42:1419\u20131429. doi: 10.1007/s11033-015-3921-7.", "ArticleIdList": ["10.1007/s11033-015-3921-7", "26311153"]}, {"Citation": "Li Y., Yao J., Han C., Yang J., Chaudhry M.T., Wang S., Liu H., Yin Y. Quercetin, Inflammation and Immunity. Nutrients. 2016;8:167. doi: 10.3390/nu8030167.", "ArticleIdList": ["10.3390/nu8030167", "PMC4808895", "26999194"]}, {"Citation": "Sur S., Pal D., Roy R., Barua A., Roy A., Saha P., Panda C.K. Tea polyphenols EGCG and TF restrict tongue and liver carcinogenesis simultaneously induced by N-nitrosodiethylamine in mice. Toxicol. Appl. Pharmacol. 2016;300:34\u201346. doi: 10.1016/j.taap.2016.03.016.", "ArticleIdList": ["10.1016/j.taap.2016.03.016", "27058323"]}, {"Citation": "Li N., Men W., Zheng Y., Wang H., Meng X. Oroxin B Induces Apoptosis by Down-Regulating MicroRNA-221 Resulting in the Inactivation of the PTEN/PI3K/AKT Pathway in Liver Cancer. Molecules. 2019;24:4384. doi: 10.3390/molecules24234384.", "ArticleIdList": ["10.3390/molecules24234384", "PMC6930563", "31801250"]}, {"Citation": "Thirusangu P., Vigneshwaran V., Avin B.V., Rakesh H., Vikas H., Prabhakar B. Scutellarein antagonizes the tumorigenesis by modulating cytokine VEGF mediated neoangiogenesis and DFF-40 actuated nucleosomal degradation. Biochem. Biophys. Res. Commun. 2017;484:85\u201392. doi: 10.1016/j.bbrc.2017.01.067.", "ArticleIdList": ["10.1016/j.bbrc.2017.01.067", "28104392"]}, {"Citation": "Yang H., Wang J., Fan J.-H., Zhang Y.-Q., Zhao J.-X., Dai X.-J., Liu Q., Shen Y.-J., Liu C., Sun W.-D., et al. Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth. Toxicol. Appl. Pharmacol. 2017;315:90\u2013101. doi: 10.1016/j.taap.2016.12.008.", "ArticleIdList": ["10.1016/j.taap.2016.12.008", "27986624"]}, {"Citation": "Li Y., Cheng X., Chen C., Huijuan W., Zhao H., Liu W., Xiang Z., Wang Q. Apigenin, a flavonoid constituent derived from P. villosa, inhibits hepatocellular carcinoma cell growth by CyclinD1/CDK4 regulation via p38 MAPK-p21 signaling. Pathol. Res. Pract. 2020;216:152701. doi: 10.1016/j.prp.2019.152701.", "ArticleIdList": ["10.1016/j.prp.2019.152701", "31780054"]}, {"Citation": "Lim W.C., Kim H., Ko H. Delphinidin inhibits epidermal growth factor-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma cells. J. Cell. Biochem. 2019;120:9887\u20139899. doi: 10.1002/jcb.28271.", "ArticleIdList": ["10.1002/jcb.28271", "30537288"]}, {"Citation": "Amin A., Hamza A.A., Bajbouj K., Ashraf S.S., Daoud S. Saffron: A potential candidate for a novel anticancer drug against hepatocellular carcinoma. Hepatology. 2011;54:857\u2013867. doi: 10.1002/hep.24433.", "ArticleIdList": ["10.1002/hep.24433", "21607999"]}, {"Citation": "Amin A., Awad B. Crocin-Sorafenib Combination Therapy for Liver Cancer. 10,933,076. U.S. Patent. 2021 March 2;"}, {"Citation": "Amin A., Al Mansoori A., Baig B. Safranal-Sorafenib Combination Therapy for Liver Cancer. 10,568,873. U.S. Patent. 2020 February 25;"}, {"Citation": "Al-Hrout A., Chaiboonchoe A., Khraiwesh B., Murali C., Baig B., El-Awady R., Tarazi H., Alzahmi A., Nelson D.R., Greish Y.E., et al. Safranal induces DNA double-strand breakage and ER-stress-mediated cell death in hepatocellular carcinoma cells. Sci. Rep. 2018;8:1\u201315. doi: 10.1038/s41598-018-34855-0.", "ArticleIdList": ["10.1038/s41598-018-34855-0", "PMC6240095", "30446676"]}, {"Citation": "Zheng T., Wang J., Song X., Meng X., Pan S., Jiang H., Liu L. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways. J. Cancer Res. Clin. Oncol. 2010;136:1597\u20131604. doi: 10.1007/s00432-010-0817-8.", "ArticleIdList": ["10.1007/s00432-010-0817-8", "20174822"]}, {"Citation": "Shimizu M., Shirakami Y., Sakai H., Tatebe H., Nakagawa T., Hara Y., Weinstein I.B., Moriwaki H. EGCG inhibits acti-vation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells. Cancer Lett. 2008;262:10\u201318. doi: 10.1016/j.canlet.2007.11.026.", "ArticleIdList": ["10.1016/j.canlet.2007.11.026", "18164805"]}, {"Citation": "Shao J., Meng Q., Li Y. Theaflavins suppress tumor growth and metastasis via the blockage of the STAT3 pathway in hepatocellular carcinoma. OncoTargets Ther. 2016;9:4265\u20134275. doi: 10.2147/OTT.S102858.", "ArticleIdList": ["10.2147/OTT.S102858", "PMC4951064", "27478384"]}, {"Citation": "Banjerdpongchai R., Wudtiwai B., Khaw-On P., Rachakhom W., Duangnil N., Kongtawelert P. Hesperidin from citrus seed induces human hepatocellular carcinoma HepG2 cell apoptosis via both mitochondrial and death receptor pathways. Tumor Biol. 2016;37:227\u2013237. doi: 10.1007/s13277-015-3774-7.", "ArticleIdList": ["10.1007/s13277-015-3774-7", "PMC4841854", "26194866"]}, {"Citation": "Shu G., Yang J., Zhao W., Xu C., Hong Z., Mei Z., Yang X. Kurarinol induces hepatocellular carcinoma cell apoptosis through suppressing cellular signal transducer and activator of transcription 3 signaling. Toxicol. Appl. Pharmacol. 2014;281:157\u2013165. doi: 10.1016/j.taap.2014.06.021.", "ArticleIdList": ["10.1016/j.taap.2014.06.021", "24997323"]}, {"Citation": "Chen W.-T., Lin G.-B., Lin S.-H., Lu C.-H., Hsieh C.-H., Ma B.-L., Chao C.-Y. Static magnetic field enhances the anticancer efficacy of capsaicin on HepG2 cells via capsaicin receptor TRPV1. PLoS ONE. 2018;13:e0191078. doi: 10.1371/journal.pone.0191078.", "ArticleIdList": ["10.1371/journal.pone.0191078", "PMC5770067", "29338036"]}, {"Citation": "Hwang Y.-J., Lee E.-J., Kim H.-R., Hwang K.-A. Molecular mechanisms of luteolin-7-O-glucoside-induced growth inhibition on human liver cancer cells: G2/M cell cycle arrest and caspase-independent apoptotic signaling pathways. BMB Rep. 2013;46:611\u2013616. doi: 10.5483/BMBRep.2013.46.12.133.", "ArticleIdList": ["10.5483/BMBRep.2013.46.12.133", "PMC4133862", "24257119"]}, {"Citation": "Lin Z., Carvalho B.R., Kahn E., Lv R., Rao R., Terrones H., A Pimenta M., Terrones M. Defect engineering of two-dimensional transition metal dichalcogenides. 2D Mater. 2016;3:022002. doi: 10.1088/2053-1583/3/2/022002.", "ArticleIdList": ["10.1088/2053-1583/3/2/022002"]}, {"Citation": "Huang C., Wei Y.-X., Shen M.-C., Tu Y.-H., Wang C.-C., Huang H.-C. Chrysin, Abundant in Morinda citrifolia Fruit Water\u2013EtOAc Extracts, Combined with Apigenin Synergistically Induced Apoptosis and Inhibited Migration in Human Breast and Liver Cancer Cells. J. Agric. Food Chem. 2016;64:4235\u20134245. doi: 10.1021/acs.jafc.6b00766.", "ArticleIdList": ["10.1021/acs.jafc.6b00766", "27137679"]}, {"Citation": "Zou M., Lu N., Hu C., Liu W., Sun Y., Wang X., You Q., Gu C., Xi T., Guo Q. Beclin 1-mediated autophagy in hepato-cellular carcinoma cells: Implication in anticancer efficiency of oroxylin A via inhibition of mTOR signaling. Cell. Signal. 2012;24:1722\u20131732. doi: 10.1016/j.cellsig.2012.04.009.", "ArticleIdList": ["10.1016/j.cellsig.2012.04.009", "22560876"]}, {"Citation": "Xu M., Lu N., Zhang H., Dai Q., Wei L., Li Z., You Q., Guo Q. Wogonin induced cytotoxicity in human hepatocellular carcinoma cells by activation of unfolded protein response and inactivation of AKT. Hepatol. Res. 2013;43:890\u2013905. doi: 10.1111/hepr.12036.", "ArticleIdList": ["10.1111/hepr.12036", "23294370"]}, {"Citation": "Liang R.R., Zhang S., Qi J.A., Wang Z.D., Li J., Liu P.J., Huang C., Le X.F., Yang J., Li Z.F. Preferential inhibition of hepatocellular carcinoma by the flavonoid Baicalein through blocking MEK-ERK signaling. Int. J. Oncol. 2012;41:969\u2013978. doi: 10.3892/ijo.2012.1510.", "ArticleIdList": ["10.3892/ijo.2012.1510", "22684543"]}, {"Citation": "Wang Y.-F., Li T., Tang Z.-H., Chang L.-L., Zhu H., Chen X.-P., Wang Y.-T., Lu J.-J. Baicalein triggers autophagy and inhibits the protein kinase B/Mammalian target of rapamycin pathway in hepatocellular carcinoma HepG2 Cells. Phytother. Res. 2015;29:674\u2013679. doi: 10.1002/ptr.5298.", "ArticleIdList": ["10.1002/ptr.5298", "25641124"]}, {"Citation": "Wang F., Wang Y.-H., Wang J.-J., Xu H.-L., Wang C.-M. Eriodictyol-induced anti-cancer and apoptotic effects in human hepatocellular carcinoma cells are associated with cell cycle arrest and modulation of apoptosis-related proteins. Bangladesh J. Pharmacol. 2016;11:285\u2013291. doi: 10.3329/bjp.v11i2.25549.", "ArticleIdList": ["10.3329/bjp.v11i2.25549"]}, {"Citation": "Zhang J., Song J., Wu D., Wang J., Dong W. Hesperetin induces the apoptosis of hepatocellular carcinoma cells via mito-chondrial pathway mediated by the increased intracellular reactive oxygen species, ATP and calcium. Med. Oncol. 2015;32:101. doi: 10.1007/s12032-015-0516-z.", "ArticleIdList": ["10.1007/s12032-015-0516-z", "25737432"]}, {"Citation": "Su L., Chen X., Wu J., Lin B., Zhang H., Lan L., Luo H. Galangin inhibits proliferation of hepatocellular carcinoma cells by inducing endoplasmic reticulum stress. Food Chem. Toxicol. 2013;62:810\u2013816. doi: 10.1016/j.fct.2013.10.019.", "ArticleIdList": ["10.1016/j.fct.2013.10.019", "24161691"]}, {"Citation": "Zhang H.-T., Luo H., Wu J., Lan L.-B., Fan D.-H., Zhu K.-D., Chen X.-Y., Wen M., Liu H.-M. Galangin induces apoptosis of hepatocellular carcinoma cells via the mitochondrial pathway. World J. Gastroenterol. 2010;16:3377. doi: 10.3748/wjg.v16.i27.3377.", "ArticleIdList": ["10.3748/wjg.v16.i27.3377", "PMC2904883", "20632439"]}, {"Citation": "Nishikawa T., Nakajima T., Moriguchi M., Jo M., Sekoguchi S., Ishii M., Takashima H., Katagishi T., Kimura H., Minami M., et al. A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins. J. Hepatol. 2006;44:1074\u20131082. doi: 10.1016/j.jhep.2005.11.045.", "ArticleIdList": ["10.1016/j.jhep.2005.11.045", "16481065"]}, {"Citation": "Huang X., Lian T., Guan X., Liu B., Hao S., Zhang J., Bao S., Tan X., Zhu R., Song Z. Dihydromyricetin reduces TGF-\u03b2 via P53 activation-dependent mechanism in hepatocellular carcinoma HepG2 cells. Protein Pept. Lett. 2017;24:419\u2013424. doi: 10.2174/0929866524666170223143113.", "ArticleIdList": ["10.2174/0929866524666170223143113", "28240161"]}, {"Citation": "Wang Z., Zhang H., Zhou J., Zhang X., Chen L., Chen K., Huang Z. Eriocitrin from lemon suppresses the proliferation of human hepatocellular carcinoma cells through inducing apoptosis and arresting cell cycle. Cancer Chemother. Pharmacol. 2016;78:1143\u20131150. doi: 10.1007/s00280-016-3171-y.", "ArticleIdList": ["10.1007/s00280-016-3171-y", "27766389"]}, {"Citation": "Youns M., Hegazy W.A.H. The natural flavonoid fisetin inhibits cellular proliferation of hepatic, colorectal, and pancreatic cancer cells through modulation of multiple signaling pathways. PLoS ONE. 2017;12:e0169335. doi: 10.1371/journal.pone.0169335.", "ArticleIdList": ["10.1371/journal.pone.0169335", "PMC5215656", "28052097"]}, {"Citation": "Mylonis I., Lakka A., Tsakalof A., Simos G. The dietary flavonoid kaempferol effectively inhibits HIF-1 activity and hepatoma cancer cell viability under hypoxic conditions. Biochem. Biophys. Res. Commun. 2010;398:74\u201378. doi: 10.1016/j.bbrc.2010.06.038.", "ArticleIdList": ["10.1016/j.bbrc.2010.06.038", "20558139"]}, {"Citation": "Liu C., Yang S., Wang K., Bao X., Liu Y., Zhou S., Liu H., Qiu Y., Wang T., Yu H. Alkaloids from traditional Chinese medicine against hepatocellular carcinoma. Biomed. Pharmacother. 2019;120:109543. doi: 10.1016/j.biopha.2019.109543.", "ArticleIdList": ["10.1016/j.biopha.2019.109543", "31655311"]}, {"Citation": "Shi L., Yang F., Luo F., Liu Y., Zhang F., Zou M., Liu Q. Evodiamine exerts anti-tumor effects against hepatocellular car-cinoma through inhibiting \u03b2-catenin-mediated angiogenesis. Tumor Biol. 2016;37:12791\u201312803. doi: 10.1007/s13277-016-5251-3.", "ArticleIdList": ["10.1007/s13277-016-5251-3", "27449032"]}, {"Citation": "Li C., Cai G., Song D., Gao R., Teng P., Zhou L., Ji Q., Sui H., Cai J., Li Q., et al. Development of EGFR-targeted evodiamine nanoparticles for the treatment of colorectal cancer. Biomater. Sci. 2019;7:3627\u20133639. doi: 10.1039/C9BM00613C.", "ArticleIdList": ["10.1039/C9BM00613C", "31328737"]}, {"Citation": "Zhao S., Xu K., Jiang R., Li D.-Y., Guo X.-X., Zhou P., Tang J.-F., Li L.-S., Zeng D., Hu L., et al. Evodiamine inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells via the Hippo-Yes-Associated Protein signaling pathway. Life Sci. 2020;251:117424. doi: 10.1016/j.lfs.2020.117424.", "ArticleIdList": ["10.1016/j.lfs.2020.117424", "32057900"]}, {"Citation": "Wiltberger G., Wu Y., Lange U., Hau H.-M., Tapper E., Krenzien F., Atanasov G., Benzing C., Feldbr\u00fcgge L., Csizmadia E., et al. Protective effects of coffee consumption following liver transplantation for hepatocellular carcinoma in cirrhosis. Aliment. Pharmacol. Ther. 2019;49:779\u2013788. doi: 10.1111/apt.15089.", "ArticleIdList": ["10.1111/apt.15089", "30811647"]}, {"Citation": "Tong D., Qu H., Meng X., Jiang Y., Liu D., Ye S., Chen H., Jin Y., Fu S., Geng J. S-allylmercaptocysteine promotes MAPK inhibitor-induced apoptosis by activating the TGF-\u03b2 signaling pathway in cancer cells. Oncol. Rep. 2014;32:1124\u20131132. doi: 10.3892/or.2014.3295.", "ArticleIdList": ["10.3892/or.2014.3295", "24970681"]}, {"Citation": "Xiao J., Xing F., Liu Y., Lv Y., Wang X., Ling M.-T., Gao H., Ouyang S., Yang M., Zhu J., et al. Garlic-derived compound S-allylmercaptocysteine inhibits hepatocarcinogenesis through targeting LRP6/Wnt pathway. Acta Pharm. Sin. B. 2018;8:575\u2013586. doi: 10.1016/j.apsb.2017.10.003.", "ArticleIdList": ["10.1016/j.apsb.2017.10.003", "PMC6090075", "30109182"]}, {"Citation": "Amin A., Hamza A.A., Daoud S., Khazanehdari K., Hrout A.A., Baig B., Chaiboonchoe A., Adrian T.E., Zaki N., Salehi-Ashtiani K. Saffron-based crocin prevents early lesions of liver cancer: In vivo, in vitro and network analyses. Recent Pat. Anti-Cancer Drug Discov. 2016;11:121\u2013133. doi: 10.2174/1574892810666151102110248.", "ArticleIdList": ["10.2174/1574892810666151102110248", "26522014"]}, {"Citation": "El-Kharrag R., Amin A., Hisaindee S., Greish Y., Karam S.M. Development of a therapeutic model of precancerous liver using crocin-coated magnetite nanoparticles. Int. J. Oncol. 2017;50:212\u2013222. doi: 10.3892/ijo.2016.3769.", "ArticleIdList": ["10.3892/ijo.2016.3769", "27878253"]}, {"Citation": "Kim B., Park B. Saffron carotenoids inhibit STAT3 activation and promote apoptotic progression in IL-6-stimulated liver cancer cells. Oncol. Rep. 2018;39:1883\u20131891. doi: 10.3892/or.2018.6232.", "ArticleIdList": ["10.3892/or.2018.6232", "29393468"]}, {"Citation": "Yao C., Liu B.-B., Qian X.-D., Li L.-Q., Cao H.-B., Guo Q.-S., Zhou G.-F. Crocin induces autophagic apoptosis in hepato-cellular carcinoma by inhibiting Akt/mTOR activity. Onco Targets Ther. 2018;11:2017. doi: 10.2147/OTT.S154586.", "ArticleIdList": ["10.2147/OTT.S154586", "PMC5898595", "29670377"]}, {"Citation": "Sawant A.V., Srivastava S., Prassanawar S.S., Bhattacharyya B., Panda D. Crocin, a carotenoid, suppresses spindle mi-crotubule dynamics and activates the mitotic checkpoint by binding to tubulin. Biochem. Pharmacol. 2019;163:32\u201345. doi: 10.1016/j.bcp.2019.01.023.", "ArticleIdList": ["10.1016/j.bcp.2019.01.023", "30710515"]}, {"Citation": "Amin A. Prevention of Liver Cancer with Safranal-Based Formulations. 10,912,741. U.S. Patent. 2021 February 9;"}, {"Citation": "Noureini S.K., Wink M. Antiproliferative effects of crocin in HepG2 Cells by telomerase inhibition and hTERT down-regulation. Asian Pac. J. Cancer Prev. 2012;13:2305\u20132309. doi: 10.7314/APJCP.2012.13.5.2305.", "ArticleIdList": ["10.7314/APJCP.2012.13.5.2305", "22901211"]}, {"Citation": "Tharehalli U., G\u00fcnes C., Lechel A. Telomeres and telomerase in the development of liver cancer. Cancers. 2020;12:2048. doi: 10.3390/cancers12082048.", "ArticleIdList": ["10.3390/cancers12082048", "PMC7464754", "32722302"]}, {"Citation": "Amin A., Bajbouj K., Koch A., Gandesiri M., Schneider-Stock R. Defective autophagosome formation in p53-null colorectal cancer reinforces crocin-induced apoptosis. Int. J. Mol. Sci. 2015;16:1544\u20131561. doi: 10.3390/ijms16011544.", "ArticleIdList": ["10.3390/ijms16011544", "PMC4307319", "25584615"]}, {"Citation": "Scheau C., Badarau I.A., Caruntu C., Mihai G.L., Didilescu A.C., Constantin C., Neagu M. Capsaicin: Effects on the pathogenesis of hepatocellular carcinoma. Molecules. 2019;24:2350. doi: 10.3390/molecules24132350.", "ArticleIdList": ["10.3390/molecules24132350", "PMC6651067", "31247901"]}, {"Citation": "Lin Y.-T., Wang H.-C., Hsu Y.-C., Cho C.-L., Yang M.-Y., Chien C.-Y. Capsaicin Induces Autophagy and Apoptosis in Human Nasopharyngeal Carcinoma Cells by Downregulating the PI3K/AKT/mTOR Pathway. Int. J. Mol. Sci. 2017;18:1343. doi: 10.3390/ijms18071343.", "ArticleIdList": ["10.3390/ijms18071343", "PMC5535836", "28644386"]}, {"Citation": "Min J.-K., Han K.-Y., Kim E.-C., Kim Y.-M., Lee S.-W., Kim O.-H., Kim K.-W., Gho Y.S., Kwon Y.-G. Capsaicin inhibits in vitro and in vivo angiogenesis. Cancer Res. 2004;64:644\u2013651. doi: 10.1158/0008-5472.CAN-03-3250.", "ArticleIdList": ["10.1158/0008-5472.CAN-03-3250", "14744780"]}, {"Citation": "Kato K., Ogura T., Kishimoto A., Minegishi Y., Nakajima N., Miyazaki M., Esumi H. Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation. Oncogene. 2002;21:6082\u20136090. doi: 10.1038/sj.onc.1205737.", "ArticleIdList": ["10.1038/sj.onc.1205737", "12203120"]}, {"Citation": "Fattori V., Hohmann M.S., Rossaneis A.C., Pinho-Ribeiro F.A., Verri W.A. Capsaicin: Current understanding of its mecha-nisms and therapy of pain and other pre-clinical and clinical uses. Molecules. 2016;21:844. doi: 10.3390/molecules21070844.", "ArticleIdList": ["10.3390/molecules21070844", "PMC6273101", "27367653"]}, {"Citation": "Bort A., S\u00e1nchez B.G., Sp\u00ednola E., Mateos-Gomez P.A., Rodr\u00edguez-Henche N., D\u00edaz-Laviada I. The red pepper\u2019s spicy ingredient capsaicin activates AMPK in HepG2 cells through CaMKK\u03b2. PLoS ONE. 2019;14:e0211420. doi: 10.1371/journal.pone.0211420.", "ArticleIdList": ["10.1371/journal.pone.0211420", "PMC6350977", "30695053"]}, {"Citation": "Bort A., Sp\u00ednola E., Rodr\u00edguez-Henche N., D\u00edaz-Laviada I. Capsaicin exerts synergistic antitumor effect with sorafenib in hepatocellular carcinoma cells through AMPK activation. Oncotarget. 2017;8:87684\u201387698. doi: 10.18632/oncotarget.21196.", "ArticleIdList": ["10.18632/oncotarget.21196", "PMC5675664", "29152112"]}, {"Citation": "Chen C., Wang L., Wang R., Luo X., Li Y., Li J., Li Y., Chen Z. Phenolic contents, cellular antioxidant activity and anti-proliferative capacity of different varieties of oats. Food Chem. 2018;239:260\u2013267. doi: 10.1016/j.foodchem.2017.06.104.", "ArticleIdList": ["10.1016/j.foodchem.2017.06.104", "28873568"]}, {"Citation": "Zhang S.S., Ni Y.H., Zhao C.R., Qiao Z., Yu H.X., Wang L.Y., Sun J.Y., Du C., Zhang J.H., Dong L.Y., et al. Capsaicin en-hances the antitumor activity of sorafenib in hepatocellular carcinoma cells and mouse xenograft tumors through increased ERK signaling. Acta Pharmacol. Sin. 2018;39:438\u2013448. doi: 10.1038/aps.2017.156.", "ArticleIdList": ["10.1038/aps.2017.156", "PMC5843835", "29188798"]}, {"Citation": "Li Q., Li L., Wang F., Chen J., Zhao Y., Wang P., Nilius B., Liu D., Zhu Z. Dietary capsaicin prevents nonalcoholic fatty liver disease through transient receptor potential vanilloid 1-mediated peroxisome proliferator-activated receptor \u03b4 activation. Pfl\u00fcgers Arch. Eur. J. Physiol. 2013;465:1303\u20131316. doi: 10.1007/s00424-013-1274-4.", "ArticleIdList": ["10.1007/s00424-013-1274-4", "23605066"]}, {"Citation": "Munson M.J., Ganley I.G. MTOR, PIK3C3, and autophagy: Signaling the beginning from the end. Autophagy. 2015;11:2375\u20132376. doi: 10.1080/15548627.2015.1106668.", "ArticleIdList": ["10.1080/15548627.2015.1106668", "PMC4835211", "26565689"]}, {"Citation": "Chen X., Tan M., Xie Z.-Q., Feng B., Zhao Z., Yang K., Hu C., Liao N., Wang T., Chen D., et al. Inhibiting ROS-STAT3-dependent autophagy enhanced capsaicin\u2013induced apoptosis in human hepatocellular carcinoma cells. Free Radic. Res. 2016;50:744\u2013755. doi: 10.3109/10715762.2016.1173689.", "ArticleIdList": ["10.3109/10715762.2016.1173689", "27043357"]}, {"Citation": "Jung M.-Y., Kang H.-J., Moon A. Capsaicin-induced apoptosis in SK-Hep-1 hepatocarcinoma cells involves Bcl-2 downreg-ulation and caspase-3 activation. Cancer Lett. 2001;165:139\u2013145. doi: 10.1016/S0304-3835(01)00426-8.", "ArticleIdList": ["10.1016/S0304-3835(01)00426-8", "11275362"]}, {"Citation": "Huang S.-P., Chen J.-C., Wu C.-C., Chen C.-T., Tang N.-Y., Ho Y.-T., Lo C., Lin J.-P., Chung J.-G., Lin J.-G. Capsaicin-induced apoptosis in human hepatoma HepG2 cells. Anticancer Res. 2009;29:165\u2013174.", "ArticleIdList": ["19331147"]}, {"Citation": "Kim J.-A., Kang Y.S., Lee Y.S. A phospholipase C-dependent intracellular Ca 2+ release pathway mediates the capsai-cin-induced apoptosis in HepG2 human hepatoma cells. Arch. Pharmacal. Res. 2005;28:73\u201380. doi: 10.1007/BF02975139.", "ArticleIdList": ["10.1007/BF02975139", "15742812"]}, {"Citation": "Waterhouse N.J., Goldstein J.C., Von Ahsen O., Schuler M., Newmeyer D.D., Green D.R. Cytochrome c maintains mito-chondrial transmembrane potential and ATP generation after outer mitochondrial membrane permeabilization during the apoptotic process. J. Cell Biol. 2001;153:319\u2013328. doi: 10.1083/jcb.153.2.319.", "ArticleIdList": ["10.1083/jcb.153.2.319", "PMC2169468", "11309413"]}, {"Citation": "Brenner C., Kroemer G. Mitochondria\u2014the death signal integrators. Science. 2000;289:1150\u20131151. doi: 10.1126/science.289.5482.1150.", "ArticleIdList": ["10.1126/science.289.5482.1150", "10970229"]}, {"Citation": "Kapetanovic I. Computer-aided drug discovery and development (CADDD): In silico-chemico-biological approach. Chem. -Biol. Interact. 2008;171:165\u2013176. doi: 10.1016/j.cbi.2006.12.006.", "ArticleIdList": ["10.1016/j.cbi.2006.12.006", "PMC2253724", "17229415"]}, {"Citation": "Mabrouk M.S. Discovering best candidates for Hepatocellular Carcinoma (HCC) by in-silico techniques and tools. Int. J. Bioinform. Res. Appl. 2012;8:141\u2013152. doi: 10.1504/IJBRA.2012.045956.", "ArticleIdList": ["10.1504/IJBRA.2012.045956", "22450276"]}, {"Citation": "Krishnan G.S., Rajagopal V., Joseph S.R.A., Sebastian D., Savarimuthu I., Selvaraj K.R.N., Thobias A.F. In vitro, in silico and in vivo antitumor activity of crude methanolic extract of tetilla dactyloidea (Carter, 1869) on DEN Induced HCC in a Rat Model. Biomed. Pharmacother. 2017;95:795\u2013807. doi: 10.1016/j.biopha.2017.08.054.", "ArticleIdList": ["10.1016/j.biopha.2017.08.054", "28892791"]}, {"Citation": "Wang W., Xiong X., Li X., Zhang Q., Yang W., Du L. In silico investigation of the anti-tumor mechanisms of epigallocate-chin-3-gallate. Molecules. 2019;24:1445. doi: 10.3390/molecules24071445.", "ArticleIdList": ["10.3390/molecules24071445", "PMC6480119", "30979098"]}, {"Citation": "Song L., Luo Y., Wang X., Almutairi M.M., Pan H., Li W., Liu Y., Wang Q., Hong M. Exploring the active mechanism of berberine against HCC by systematic pharmacology and experimental validation. Mol. Med. Rep. 2019;20:4654\u20134664. doi: 10.3892/mmr.2019.10698.", "ArticleIdList": ["10.3892/mmr.2019.10698", "PMC6797955", "31545468"]}, {"Citation": "Lagoa R., Silva J., Rodrigues J.R., Bishayee A. Advances in phytochemical delivery systems for improved anticancer activity. Biotechnol. Adv. 2020;38:107382. doi: 10.1016/j.biotechadv.2019.04.004.", "ArticleIdList": ["10.1016/j.biotechadv.2019.04.004", "30978386"]}, {"Citation": "Zi C.-T., Wang Z.-H., Shi J., Shi B.-Y., Zhang N., Wu Y.-L., Xie Y.-R., Zhou L., Xiao C., Wang X.-J., et al. Synthesis, cytotoxicity, and molecular docking of methylated (\u2013)-epigallocatechin-3-gallate-4\u03b2-triazolopodophyllotoxin derivatives as novel antitumor agents. J. Chem. Res. 2021:17475198211027328. doi: 10.1177/17475198211027328.", "ArticleIdList": ["10.1177/17475198211027328"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "8", "Day": "30"}, {"Year": "2021", "Month": "9", "Day": "25"}, {"Year": "2021", "Month": "9", "Day": "26"}, {"Year": "2021", "Month": "10", "Day": "13", "Hour": "1", "Minute": "5"}, {"Year": "2021", "Month": "10", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "10", "Day": "26", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "10", "Day": "6"}], "PublicationStatus": "epublish", "ArticleIdList": ["34639131", "PMC8509806", "10.3390/ijms221910774", "ijms221910774"]}}], "PubmedBookArticle": []}